Lipoic Acid Choline Ester Presbyopia Treatment via Non-Aqueous Excipient
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Presbyopia, a condition where the ability to focus on near objects decreases with age due to physiological changes in the lens, leading to a loss of accommodative amplitude, is not effectively addressed by existing treatments, as the critical fluid layer responsible for lens geometry changes is compromised by disulfide cross-linking.
Innovation Solution
A pharmaceutical composition comprising lipoic acid choline ester or its derivatives combined with a non-aqueous excipient, formulated in an aqueous solution with a pH of 4 to 8, which restores the critical fluid layer and reduces lens cytosol modulus, thereby treating ocular diseases like presbyopia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipoic acid choline ester is formulated in aqueous solution, then it can restore the critical fluid layer and treat presbyopia, but it degrades over time with increased impurities
Solution Approach 1:
The patent introduces a non-aqueous excipient as an intermediary substance that forms a separate phase or complex with lipoic acid choline ester. This intermediary protects the active ingredient from aqueous degradation while still allowing it to function therapeutically in the eye, thus resolving the contradiction between maintaining therapeutic effectiveness and preventing chemical degradation.
Solution Approach 2:
The patent creates a composite formulation combining lipoic acid choline ester with specific non-aqueous excipients. This composite structure provides both the therapeutic properties of the active ingredient and the stability benefits of the excipient system, allowing the formulation to maintain both effectiveness and chemical stability simultaneously.
2Ease of operation
If lipoic acid choline ester is stored in aqueous solution, then it remains soluble and administrable, but it experiences degradation and forms impurities
Solution Approach 1:
The patent segments the formulation into distinct aqueous and non-aqueous phases. The lipoic acid choline ester is incorporated into the non-aqueous phase which is separate from the aqueous vehicle, allowing the active ingredient to maintain solubility and administerability while being protected from aqueous degradation pathways.
Solution Approach 2:
The non-aqueous excipient acts as a protective intermediary that prevents direct contact between lipoic acid choline ester and aqueous degradation environments, while still permitting the formulation to be administered through aqueous tear film. This intermediary function eliminates degradation without compromising ease of administration.
3Reliability
If existing treatments are used for presbyopia, then they can provide corrective effect, but they do not address the underlying disulfide cross-linking issue
Solution Approach 1:
The patent converts the harmful disulfide cross-linking mechanism into a beneficial target for therapy. By using lipoic acid choline ester, which specifically addresses disulfide bond formation, the treatment transforms the understanding of the disease mechanism from a passive corrective approach to an active reversal of the underlying molecular pathology, providing both corrective effect and mechanistic insight.
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of lipoic acid choline ester or derivatives thereof and a non-aqueous excipient mixed in an aqueous solution. Also provided herein are non-aqueous compositions prepared by mixing the therapeutically effective amount of lipoic acid choline ester and the non-aqueous excipient. The non-aqueous compositions can be further mixed with the aqueous solution.